Data updated: Mar 10, 2026
SEGLENTIS
CELECOXIB
Approved 2021-10-15
1
Indication
--
Phase 3 Trials
4
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2021-10-15
- Routes
- ORAL
- Dosage Forms
- TABLET
SEGLENTIS Approval History
Loading approval history...
What SEGLENTIS Treats
1 FDA approvalsOriginally approved for its first indication in 2021 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
SEGLENTIS FDA Label Details
ProSEGLENTIS Patents & Exclusivity
Latest Patent: Jun 2031
Patents (7 active)
US8846744
Expires Jun 3, 2031
US10238668
Expires Apr 19, 2030
US10548909
Expires Apr 19, 2030
US11478488
Expires Apr 19, 2030
US9012440
Expires Apr 19, 2030
US10245276
Expires Apr 19, 2030
US8598152
Expires Apr 19, 2030
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.